Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
about
Risk factors in coronary atherosclerosis athero-inflammation: the meeting pointPersonalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsAntiplatelet agents in atherothrombotic diseasesStent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapyPlatelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Acute coronary syndromes: diagnosis and management, part IThe Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions.Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.Pharmacogenomics of cardiovascular complications in diabetes and obesity.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyChanging roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.Tirofiban in acute coronary syndromes.Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents.Acute coronary syndromes and diabetes mellitus.Biomarkers in acute coronary syndromes and their role in diabetic patients.Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome.The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes.Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents.Gender-related mortality trends among diabetic patients with ST-segment elevation myocardial infarction: insights from a nationwide registry 1997-2010Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregationAntiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Current concepts on coronary revascularization in diabetic patients.Variability of clopidogrel response in patients with type 2 diabetes mellitus.Arterial thrombosis--insidious, unpredictable and deadly.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventiAntithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization?Diabetes mellitus and the heart.Platelet function profiles in patients with diabetes mellitus.Percutaneous coronary intervention in diabetic patients: should choice of stents be influenced?Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
P2860
Q24793107-0A7EDBC1-F019-4721-870F-9CA9BBE05687Q26775125-29787DC4-89C2-472C-B783-75AB976DE1BCQ28167559-DEBBC95F-01C9-46AB-A1E5-0F7E9551AB13Q28218066-6B5B14F6-D72A-4581-AAF7-9E760DF728E6Q28219354-2A7C2B15-79E1-4690-A1CD-34524B91C0BDQ30490718-A1A8197D-10AC-4328-A595-AE94F5B4E677Q33387192-8C70F18C-F587-4614-89F1-B330A6C5EC4FQ33393501-0FCCF09D-3D07-4475-9E2D-2A2B48D6CB41Q33876187-2BCAA0D9-2F1E-424E-B189-53B7E688453DQ35141772-BDDDB604-54A2-490F-AF5B-9B1038997D71Q35195203-9826A240-33F5-48D3-B1E0-71A7F89721EFQ35647167-0173429B-9F7C-4986-9573-76A2565B6340Q35755253-9C115A00-EFD0-4E69-A7BA-16241C1D68F5Q35808289-89A7BAE4-648A-48E3-9BD3-A6C74643270DQ36107187-89F27025-6F55-418E-A5B8-27927F51E436Q36216817-689AE10C-640B-4234-831D-650766EE8925Q36320553-10D3DB94-5DBD-4967-8966-18DB9DCFCB96Q36333917-304EC72D-6DB8-4040-8541-F58F4551CBD7Q36333923-4A2B480F-FE40-4117-B089-9FFBD12BB883Q36333927-27B00DAD-DBF3-4D08-91B6-B779AA0DA136Q36519924-ABA84920-2BFF-4280-B20A-8019287EC388Q36815950-19F15836-BFDE-4246-9FC6-855494C9750BQ37184596-190DB16B-EC9A-4353-A86E-6882194BC893Q37291908-5905E82B-6A04-43FA-8432-138199BA18A2Q37334725-14FAD4B6-D628-46CD-94E8-D5751AB727EBQ37428365-A36A452E-1B29-41D6-BAE0-B8719488C2C2Q37472064-31F2D570-6DF5-42EB-8B40-DE6891B54F80Q37797795-9B23774D-5EC3-4140-B75D-16CA36179A82Q37827882-80E21463-8283-4E79-A3DF-31266664C489Q37926750-8BE1B3D9-53A2-4731-9830-F848BB2634BDQ37936014-51FBF007-3520-4060-B5F3-129BE691313DQ37953778-53D5F9E2-D40A-4E66-8F0F-3199D2F248FBQ37953885-B33FF0BA-7980-4088-B807-BA4FCCBECD81Q37997963-B98A279D-C56F-4393-ABD5-7DA5826C46D2Q38009702-8A7DE887-27BD-448A-8EAB-3F4E71B6D02BQ38018724-C8162C6F-2B9D-4A2C-A736-D57EC1EAFCDAQ38081078-F0E1852F-9312-449F-9F89-BF1D729ABA06Q38101961-505CC9B9-5476-45F1-9FCE-34A424F8E895Q38118745-17BDCFE0-30F4-45B2-BF15-0ECA479D344EQ38378830-DF026A3E-DAD3-4AA3-9FD1-57537C17EA6A
P2860
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.
@en
Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.
@nl
type
label
Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.
@en
Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.
@nl
prefLabel
Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.
@en
Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.
@nl
P2093
P356
P1433
P1476
Platelet glycoprotein IIb/IIIa ...... tion acute coronary syndromes.
@en
P2093
Heeschen C
Kleiman NS
Moliterno DJ
Mukherjee D
P304
P356
10.1161/HC4801.100029
P407
P577
2001-12-01T00:00:00Z